Mankind Pharma Q2 profit up 38% as revenue rises 17%
Mankind Pharma's second-quarter FY27 profit after tax rose 37.7% and revenue 17.3%, with EBITDA margin reaching 27.1%. Source: Moody's.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to Moody's, revenue from operations at Indian drugmaker Mankind Pharma rose 17.3% year on year in the second quarter of FY27, which ended on 30 September 2026, reaching Rs 4,338 crore. Profit after tax climbed 37.7% to Rs 716 crore. EBITDA grew 27.2% to Rs 1,175 crore, and its margin widened by 210 basis points to 27.1%.
Domestic revenue excluding consumer healthcare grew 15.9%, while exports rose 32.7%. Consumer healthcare, by contrast, added just 1.2%, reflecting slower category growth and regional pressures. For the first half of FY27, revenue reached Rs 8,368 crore and profit rose 33.7%.
The company also announced the acquisition of Armed Cell Therapeutics, which gives it a foothold in next-generation CAR-T therapies.
why it matters
The results point to strong operating momentum at a large Indian pharma company, with its sales growing faster than the market's 14.2% rate. The news matters mainly to sector investors, with limited impact on the broader market.
market impact
Indian pharma sector: strong results and export growth support sentiment around Mankind Pharma
tags
instruments
sources
- Mankind Pharma Q2 Profit Rises 38% As Revenue Grows 17% — Moody's, 27 October 2026 at 07:27 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗